comparemela.com

Latest Breaking News On - Ipilimumab - Page 1 : comparemela.com

Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation

Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

European medicines agencyBristol myers squibb coBristol myers squibbBlinded independent clinical reviewMetastatic colorectal cancerBristol myers squibbHeckmate 8hw study

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.

United kingdomLindy durrantUniversity of nottinghamAcademic department of clinical oncologyAcademic departmentClinical oncology

When Does the PD-1 Inhibitor Come Before the Hedgehog Inhibitor for Neoadjuvant BCC/CSCC?

Experts discuss when to use the PD-1 inhibitor cemiplimab vs the hedgehog inhibitor vismodegib as neoadjuvant treatment in non-melanoma skin cancers.

United statesUniversity of california san franciscoVishala patelRebeccai hartmanAnne lynns changMichaelr migdenSarah arronJohnm strasswimmerDermatology associates of the palm beachesDepartment of dermatologyPeninsula dermatology medical group in burlingameHarvard medical schoolGw cancer centerRegeneron pharmaceuticals incUniversity of texas md anderson cancer centerEuropean union

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

Advanced renal cell carcinomaTerm follow upRenal cell carcinomaAdvanced rccCheckmate 214Metastatic clear cell rccCtla4 inhibitionMetastatic clear cell renal carcinoma

First-Line Treatments for Advanced Clear Cell RCC

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Advanced renal cell carcinomaLine treatmentsAdvanced clear cellRenal cell carcinomaAdvanced rccClear cell renal carcinomaNon clear cell renal carcinomaIo tkiRisk stratification

vimarsana © 2020. All Rights Reserved.